TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01025414
Drug: Parenteral nutrition
Normalized name: parenteral nutrition solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parenteral nutrition was started 2 to 4 hours after venous catheter placement (standard Arrow type, the tip located 5 cm over right vestibule, the location confirmed on chest X-ray) and continued until oral diet covering at least 60% of daily caloric and protein demand. The energy requirements were calculated using following rule: 0.15-0.2 gN/ kg and 130-170 kcal/ gN. Parenteral diets: Aminoplasmal 10%, Lipofundin LCT/MCT 10 and 20%, 40% Glucose, Tracutil (microelements and trace elements), Cernevit (vitamins), electrolytes
Study: NCT01802021
Drug: Astagalus-based Formula: Qingshu-Yiqi-Tang
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plus astragalus-based formula: Qingshu-Yiqi-Tang 7.2gm BID during 1st line chemotherapy and 2nd line target therapy.~maximal for 6 months
Study: NCT02567279
Drug: Placebo subcutaneous injections
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous injection of Placebo, one injection at baseline and another injection at 6 months
Study: NCT02532309
Drug: Rosuvastatin (5mg，10mg，20mg)
Normalized name: ezetimibe 10 MG / rosuvastatin 20 MG [Roszet]
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Rosuvastatin dose adjusted by LDL-c level( If LDL-C\>1.1mmol/L and \<1.8mmol/L, administrated as 5mg/day.If LDL-C ≥1.8mmol/L, adjusted every 4 weeks as 5mg，10mg，20mg.
Study: NCT02532309
Drug: Rosuvastatin 5mg
Normalized name: ROSUVASTATIN 5MG CAP,SPRINKLE
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Rosuvastatin 5mg/day
Study: NCT06768632
Drug: Group 1: single-dose of test formulation+single-dose of reference formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eltrombopag Tablets is a small molecule non peptide thrombopoietin receptor agonist.
Study: NCT02497911
Drug: Ropivicaine
Normalized name: Ropivicaine-Sufentanil Citrate
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT06770894
Drug: Placebo Tablets
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets 1 a day, provided in identical blisters.
Study: NCT02574065
Drug: L. reuteri DSM 17938
Approvals — FDA: no, EMA: no, PMDA: no
Description: Effects on crying time in colicky infants with the supplementation of Lactobacillus reuteri DSM 17938
Study: NCT04292444
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The placebo nasal sprays contain identical ingredients except for the peptide itself (30 minutes before the start of the tasks).
Study: NCT01087008
Drug: zoledronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Zoledronic acid 4 mg every 4 weeks for a total of 12 treatments
Study: NCT02696148
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: For subcutaneous (s.c., under the skin) injection once daily.
Study: NCT03317600
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intervention is a placebo nerve block with isotonic saline
Study: NCT00781976
Drug: AZD7295
Approvals — FDA: no, EMA: no, PMDA: no
Description: 700mg per day maximum
Study: NCT00781976
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: matched placebo
Study: NCT03292250
Drug: BYL719
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will be instructed to take BYL719 orally at a dose of 100 mg with a glass of water once daily, in a fasting state or with a light fat-free meal, and as close as possible to the same time each day.
Study: NCT02045901
Drug: Placebo (Sugar Pill)
Normalized name: placebo Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: On Day 1, all participants will take 2 tablets of Placebo at bedtime. On Days 2 to 14, participants will take 2 tablets of Placebo at bedtime. The minimum dosage will be 2 tablets daily at bedtime, increasing, when indicated, to the maximal dosage of 4 tablets per day on Days 3 to 14.
Study: NCT00128401
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01375946
Drug: AG200-15
Approvals — FDA: no, EMA: no, PMDA: no
Description: There will be three treatment periods. Subjects will be randomly assigned to one of the five conditions for the treatment period. The subject will be exposed daily to the condition assigned while wearing the patch. The study patch will be worn for a 7 day treatment period, followed by a 7 day washout period. The total duration of the study is 6 weeks.
Study: NCT00015886
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 350 milligrams intraveneously
Study: NCT05237323
Drug: mycophenolate mofetil 2 g per day
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: mycophenolate mofetil 2 g per day and methylprednisolone in an average starting dose 24 \[24; 32\] mg per day and standard drug therapy for heart failure.
Study: NCT01587534
Drug: Norzyme
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will be randomized to receive either pancreatic enzyme replacement therapy or placebo. Patients will use two capsules three times daily during main meals and one capsule three times daily during in between snacks. The pancreatic enzyme preparation under investigation is Norzyme ® 6 - 9 tablets per day.
Study: NCT00003334
Drug: pegylated liposomal doxorubicin hydrochloride
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01001052
Drug: Colcrys™ (colchicine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.6 mg taken by mouth on day 1
Study: NCT01764737
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: single dose intravenous administration
Study: NCT02370238
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo oral tablets 1200 mg t.i.d. continuing from D 1 to Day 21 of 28-day cycle
Study: NCT02134990
Drug: Oshadi D and Oshadi R
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti cancer agents
Study: NCT02819284
Drug: KPI-121 0.25% Ophthalmic Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02819284
Drug: Vehicle of KPI-121 0.25% Ophthalmic Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00943748
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: A standard dose-escalation phase will first be initiated, with a 3 ml of the placebo oral solution twice a day (breakfast and dinner) increase every 3 days up to a total of a fixed dose of 9 ml of placebo oral solution twice a day corresponding to 30 mg/kg/day in 2 doses
Study: NCT01656057
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen dissolved in 50 ml of water
Study: NCT00000543
Drug: calcium
Normalized name: Calcium
DrugBank: Calcium sulfate (DB15533)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03936933
Drug: ZOLADEX® 3.6mg Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.6 mg, Subcutaneously at every 28 days
Study: NCT03517501
Drug: ART-123
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dose: 0.06 mg/kg/day up to a maximum dose of 6 mg/day for 6 days
Study: NCT03517501
Drug: Placebo Comparator - Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose: 0.06 mg/kg/day up to a maximum dose of 6 mg/day for 6 days
Study: NCT06773429
Drug: E2 Valerate
Normalized name: valerate
Approvals — FDA: no, EMA: no, PMDA: no
Description: To experimentally elevate E2 levels females received 6mg of E2 valerate (Progynova21©) on two consecutive days (in total 12mg).
Study: NCT06773429
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo pills (blue-colored hard gelatine capsules filled with a mixture of 99.5% mannitol and 0.5% Aerosil (fumed silica)) have been administered for the placebo-controlled condition.
Study: NCT04575610
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo tablets will be administered.
Study: NCT00671216
Drug: GSK233705
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive 200 (mcg) microgram once daily as a single dose
Study: NCT00671216
Drug: GW642444
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive 50 mcg once daily as a single dose
Study: NCT00671216
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matching study medication will be inhaled by subjects
Study: NCT01948895
Drug: Desvenlafaxine
Normalized name: Desvenlafaxine
DrugBank: Desvenlafaxine (DB06700)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will be initiated on 50 mg/day of Desvenlafaxine. No dose changes will be allowed for the first four weeks. If there is partial or no response after four weeks, dosage will then be increased to 100mg/day, based on tolerability and the Investigator's judgment.
Study: NCT03757858
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive standard chemotherapy until disease progression, unacceptable toxicity or patient refusal.
Study: NCT03535935
Drug: Astragalus Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 grams of water soluble astragalus sachets (equivalent to 15g raw herbs) administrated orally on top of standard medical care for 48 weeks.~Patients will have 5 days of medicine per week and will be advised to take the medicine once daily dissolved in boiling water in the first 5 days of the week.
Study: NCT02131012
Drug: Intravitreal Celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1-4 mg intravitreal celecoxib
Study: NCT00455156
Drug: 150 mg of Nestorone and 15 mg of ethinyl estradiol (150/15 NES/EE CVR)
Normalized name: ethinyl estradiol 0.15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg of Nestorone and 15 mg of ethinyl estradiol (150/15 NES/EE CVR), administered via vaginal ring, used on a 21/7 days in/out schedule for no more than one year.
Study: NCT00708110
Drug: GSK1349572
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK1349572 is an experimental drug being developed for the treatment of HIV. It is in the class of integrase inhibitors.
Study: NCT00708110
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo is a tablet with no drug in it.
Study: NCT00808951
Drug: Artemether-lumefantrine
Normalized name: artemether-lumefantrine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Artemether-lumefantrine by Novartis was the first fixed-dose ACT that was prequalified by WHO in April 2004. A 3-day, 6-dose regimen of AL is recommended for infants and children weighing 5-35 kg and adults weighing \> 35 kg.
Study: NCT01356875
Drug: HIDRA/VPA
Approvals — FDA: no, EMA: no, PMDA: no
Description: In each cycle (30 days), Hydralazine 50mg tablets every 12 hours and Valproic 500mg tablets every 8 hours will be administrated orally to HYDRA / VPA group.Each patient will receive 6 cycle.
Study: NCT02611466
Drug: ASP7962
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants receive ASP7962 100 mg orally twice daily, in the morning and evening with or without food (approximately 12 hours).
Study: NCT02611466
Drug: Naproxen
Normalized name: Naproxen
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants receive naproxen 500 mg orally twice daily, in the morning and evening with or without food (approximately 12 hours).
Study: NCT02611466
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants receive matching placebo orally twice daily, in the morning and evening with or without food (approximately 12 hours).
Study: NCT06782022
Drug: 5-Fluoro-Uracil
Normalized name: Fluoro Uracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients without common DPYD variant will be used for this study as a control group. Patients will receive the first 5-FU-dose based on their body surface area. 5-FU plasma concentrations will be measured during cycle 1. If patients experience CTC grade 3-4 toxicity, DPYD sequencing will be performed. Dose reduction or discontinuation of 5-FU therapy will be considered according to the physician's discretion.~Patients with a DPYD variant will receive the first dose based on their body surface area and gene activity score according to Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline or according to the physician's descretion. Patients' blood sample will be collected and the 5-FU dose for the next cycle will be calculated according to a modified algorithm of Goirand or according to the pharmacist's discretion. 5-FU plasma concentrations will be monitored until a steady state AUC of 20-30 mg.h/L is reached.
Study: NCT03714828
Drug: Injection of TVEC into target lesions - week 1-2
Normalized name: scabies lesion lysate (human)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Target lesions are identified and documented with measurements and photographs. Photographs will be taken with regional and close up view of the anatomical area and lesion.~Inject 0.5ml - 4ml (based on lesion size - section 7.1, Table 5) Talimogene laherparepvec at nominal concentration of 106 plaque forming units (PFU)/mL with approximately 1.15 mL in a 2 mL vial for the initial dose. This will be administered intralesionally to 1-3 cSCC lesions per anatomical site with a maximum of 5 injectable lesions per patient.
Study: NCT03869892
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Film-coated tablets, Capecitabine (1250 mg/m²/dose) will be administered orally BID on Days 1-14 of each cycle. This treatment cycle will be repeated every 3 weeks.
Study: NCT03714828
Drug: Injection of TVEC into target lesions 3wks after 1st injection
Normalized name: scabies lesion lysate (human)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Target lesions are identified and documented with measurements and photographs. Photographs will be taken with global and close up view of the anatomical area and lesion.~Inject 0.5ml - 4ml (based on lesion size) and number of lesions selected. Talimogene laherparepvec at nominal concentration of 108 PFU/mL with approximately 1.15 mL in a 2 mL vial for the second and subsequent doses.
Study: NCT03714828
Drug: Injection of TVEC into target lesions 2wks after 2nd injection
Normalized name: scabies lesion lysate (human)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Target lesions are identified and documented with measurements and photographs. Photographs will be taken with global and close up view of the anatomical area and lesion.~Inject 0.5ml - 4ml (based on lesion size) and number of lesions selected.Talimogene laherparepvec at nominal concentration of 108 PFU/mL with approximately 1.15 mL in a 2 mL vial for the subsequent doses.
Study: NCT03714828
Drug: Injection of TVEC into target lesions 2wks after 3rd injection
Normalized name: scabies lesion lysate (human)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Target lesions are identified and documented with measurements and photographs. Photographs will be taken with global and close up view of the anatomical area and lesion.~Inject 0.5ml - 4ml (based on lesion size) and number of lesions selected. Talimogene laherparepvec at nominal concentration of 108 PFU/mL with approximately 1.15 mL in a 2 mL vial for the subsequent doses.
Study: NCT02616666
Drug: Standard of Care
Approvals — FDA: no, EMA: no, PMDA: no
Description: The comparator arm consists of SOC. The SOC arm can be sulphonylurea (SU) or non-SU treatments. SU treatments will include any SU and the related insulin secretagogues repaglinide or nateglinide, each of them in combination with metformin. The non-SU treatments can be metformin and dipeptidyl peptidase 4 inhibitors (DPP-4i), or metformin and glitazones (pioglitazone) combination therapy. Other SGLT-2 inhibitors are excluded. All these treatments are approved in the UK for use in this patient population.
Study: NCT01998841
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered as per the schedule specified in the treatment arm.
Study: NCT02586155
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsule manufactured to mimic RVX000222 100 mg capsule
Study: NCT02586155
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: High-Intensity Statin
Study: NCT00141778
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo taken once a day
Study: NCT00141778
Drug: Spironolactone
Normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Taken orally, once a day
Study: NCT03093701
Drug: TLC399 (ProDex)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2-vial system: TLC399-DSP and TLC399-Lipid
Study: NCT02258763
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo made to look like the study drug-main ingredient sugar syrup made by the pharmacy department in the hospital In the placebo arm, patient will be given 3 days of antibiotic followed by 7 days of placebo
Study: NCT03682172
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Four hour intravenous infusion with saline water
Study: NCT00902044
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide will be administered for 2 days.~Fludarabine and cyclophosphamide will be given for 2 days, followed by fludarabine alone for the next 3 days, followed by 2 days of rest, before the T cells will be administered.~Cyclophosphamide Dose:~30 mg/kg/day IV over 1 hour (with Mesna and IV hydration)~Fludarabine Dose:~\>10 kg: 25 mg/m2/day; \<10 kg: 1 mg/kg/day IV over 30 minutes
Study: NCT04683250
Drug: TAS0953/HM06
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phase 1: oral, starting dose 20mg twice a day, until recommended phase 2 dose, continuous daily dosing, cycles lasting 21 days
Study: NCT04683250
Drug: TAS0953/HM06
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phase 2: oral, recommended dose twice a day, continuous daily dosing, cycles lasting 21 days
Study: NCT04005066
Drug: Elunate®
Approvals — FDA: no, EMA: no, PMDA: no
Description: The recommended dose is 5 mg once daily (1 capsule, each capsule contains 5 mg of fruquintinib); three weeks of continuous drug administration followed by one week of drug free period (4 weeks as one treatment cycle).
Study: NCT02891668
Drug: Levothyroxine treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eltroxin/Euthyrox is part of the normal treatment for hypothyroidism, and the patient is treated equally, whether he/she participates or not.
Study: NCT02636569
Drug: topical diclofenac daily
Normalized name: diclofenac Topical Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical diclofenac will be applied daily for 30 days. Each subject will be seen for a screening visit as well as a baseline visit and a visit at month 1. As part of the study small biopsies will be taken from three locations at the baseline visit. The biopsy will be taken from one actinic keratosis, one sun exposed area and one not sun exposed area. A biopsy is a small surgical procedure where a small piece of your skin is removed.~After applying the medications for 30 days you will return to the clinic for your 30 day visit. At this visit you will again have three biopsies taken; one AK, one sun exposed, and one non sun exposed.
Study: NCT02636569
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo Each subject will be seen for a screening visit as well as a baseline visit and a visit at month 1. As part of the study small biopsies will be taken from three locations at the baseline visit. The biopsy will be taken from, one actinic keratosis, one area that is typically exposed to the sun as well as a site that is typically protected from sun light. A biopsy is a small surgical procedure where a small piece of your skin is removed.~After applying the medications for 30 days you will return to the clinic for your 30 day visit. At this visit you will again have two biopsies taken. One of these biopsies will be from the skin on your arm that was treated with medication for the prior 30 days, and the other biopsy will be from a site that typically is not exposed to the sun.
Study: NCT01746849
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02970500
Drug: Placebo Group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT00709969
Drug: Artemether-lumefantrine
Normalized name: artemether-lumefantrine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20mg artemether and 120 mg lumefantrine, tablet, dose based on body weight, 3 days treatment 5 - \< 10kg (BWG 1) = 6 doses of 1 tablet / 10 - \< 15kg (BWG 2) = 6 doses of 1 tablet / 15 - ≤ 25kg (BWG 3) = 6 doses of 2 tablets
Study: NCT00931372
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous injection
Study: NCT00379613
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: After induction of anesthesia an intubation dose of NMBA was administered IV: 1.2 mg/kg rocuronium (arms 2-6)~At 5 minutes after administration of rocuronium, the randomized single dose of sugammadex 2.0 to 16.0 mg/kg IV was administered
Study: NCT00642512
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT03889743
Drug: placebo treatment during 3 days
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1,0 mg oral tablets. The exact daily dose of lactose (instead of dexamethasone) will be 0.3 mg/kg (maximum 6.0 mg). The recommended administration of all tablets is to crush the tablets to a smooth powder and then mix with jelly or yogurt. The dissolved dexamethasone is given by mouth and it is recommended to give it in relation to a meal/breastfeeding. If a child vomits within 30 min, the same dose will be given one more time after a break.
Study: NCT00169169
Drug: ACVBP
Normalized name: ACVBP
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00169169
Drug: ACE
Normalized name: Acet
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02210364
Drug: capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: capecitabine 150 mg tablets
Study: NCT00302796
Drug: Bioclavid
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 + 125 mg times 3 or 6
Study: NCT00302796
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03621605
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered by slow IV infusion or SC injection.
Study: NCT01505296
Drug: Antiarrhythmic drug
Normalized name: ANTIARRHYTHMICS
Approvals — FDA: no, EMA: no, PMDA: no
Description: propafenone, flecainide, sotalol, dofetilide
Study: NCT03302338
Drug: placebo group
Approvals — FDA: no, EMA: no, PMDA: no
Description: distilled water 20 ml/kg/day for maximum of 7 days.
Study: NCT01421563
Drug: Anplag
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sarpogrelate HCl 300mg once a day or 100mg three times a day